Home › Funds › Yakira Capital Management, Inc. › RNA

Yakira Capital Management, Inc. position in RNA

ATRIUM THERAPEUTICS INC · Health Care

Yakira Capital Management, Inc. reported holding 133,047 shares of RNA (ATRIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.8M, representing 0.51% of its reported portfolio and ranking #43 among its reported holdings. Yakira Capital Management, Inc. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)133.05K sh
Reported value held$1.79M
Portfolio Weight0.51%
First reportedQ1 2026
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Yakira Capital Management, Inc.'s RNA position evolved

Yakira Capital Management, Inc. first disclosed a stake in RNA in Q1 2026 at 126,645 shares (US$1.7M). The position peaked in Q2 2026 at 133,047 shares, worth US$1.8M. Across 2 filings, Yakira Capital Management, Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 133,047 shares valued at US$1.8M — an increase of 6,402 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q1 2026 126.64K $1.69M New
Q2 2026 133.05K $1.79M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RNA and 13F data

RNA (ATRIUM THERAPEUTICS INC) is a Health Care company. 116 other funds we track also report a position in RNA — the largest reported positions include Sessa Capital IM, L.P. (US$20.2M), CRCM LP (US$8.6M), TIG Advisors, LLC (US$7.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RNA

All RNA fund holders →

FAQ

How long has Yakira Capital Management, Inc. held RNA?

Yakira Capital Management, Inc. has disclosed RNA holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Yakira Capital Management, Inc.'s current position in RNA?

As of Q2 2026, Yakira Capital Management, Inc. holds 133.05K shares of RNA (ATRIUM THERAPEUTICS INC), valued at $1.79M, representing 0.51% of its reported portfolio and ranking #43.

Has Yakira Capital Management, Inc. been buying or selling RNA?

In the latest 13F filing (Q2 2026), Yakira Capital Management, Inc. increased its position in RNA. The position peaked in Q2 2026 at 133.05K shares.

Which other funds hold RNA?

Other major institutional holders of RNA include Sessa Capital IM, L.P., CRCM LP, TIG Advisors, LLC, among 116 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.